[Pituitary adenomas].
Hypophysenadenome.
Acromegaly
Chemotherapy
Cushing’s disease
Prolactinoma
Transsphenoidal surgery
Journal
Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
pubmed:
19
4
2019
medline:
3
9
2019
entrez:
19
4
2019
Statut:
ppublish
Résumé
Despite characteristic symptoms the diagnosis of clinically relevant pituitary adenomas is often delayed until an advanced stage due to the rarity of the disease. The typical clinical manifestations are presented in this review article. The recent discovery of the USP8 mutation in Cushing's disease and of X‑linked acrogigantism (X-LAG) syndrome in early onset gigantism were milestones in the search for the molecular etiology of pituitary adenomas. The triad of endocrinological, radiological and ophthalmological diagnostics are the main pillars for the diagnostic work-up of pituitary adenomas. The standard treatment modalities, which include surgery, medical treatment and irradiation, have been further developed and refined. For transsphenoidal excision of pituitary adenomas, microsurgery and endoscopy are two equivalent surgical techniques with relatively few complications. Surgery represents the first-line treatment of pituitary adenomas. Prolactinomas are an exception as the medical treatment with dopamine agonists is highly efficient. Nowadays, new medical treatment options are available for acromegaly and Cushing's disease and are used for second-line treatment. The alkylating chemotherapeutic agent temozolomide is used for the first-line chemotherapy of rare aggressively growing pituitary adenomas. Irradiation is indicated if surgical and medical treatment options are insufficiently successful. Stereotactic one-stage irradiation (radiosurgery) is especially suitable for well-demarcated invasive residual or recurrent adenomas in the cavernous sinus. A new development is hypofractionated radiosurgery for protection of structures at risk. Fractionated irradiation is necessary with large radiation volumes and for pituitary adenomas with a close proximity to the optic tract.
Identifiants
pubmed: 30997549
doi: 10.1007/s00115-019-0708-4
pii: 10.1007/s00115-019-0708-4
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
568-577Références
Cancer. 2004 Aug 1;101(3):613-9
pubmed: 15274075
J Clin Endocrinol Metab. 2006 Apr;91(4):1239-45
pubmed: 16403824
J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75
pubmed: 16968795
Acta Neurochir (Wien). 2007 Jan;149(1):21-9; discussion 29
pubmed: 17086476
J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62
pubmed: 18413427
Neurosurgery. 2008 Jun;62(6):1271-6; discussion 1276-8
pubmed: 18824993
Clin Endocrinol (Oxf). 2009 Nov;71(5):709-14
pubmed: 19302582
J Clin Endocrinol Metab. 2010 Jan;95(1):43-51
pubmed: 19880787
J Clin Endocrinol Metab. 2010 Mar;95(3):1025-33
pubmed: 20130078
J Clin Neurosci. 2011 Oct;18(10):1340-5
pubmed: 21782447
Clin Endocrinol (Oxf). 2012 Nov;77(5):728-34
pubmed: 22747829
Neurosurg Clin N Am. 2012 Oct;23(4):571-86
pubmed: 23040744
Eur J Endocrinol. 2012 Dec 10;168(1):39-47
pubmed: 23087126
J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):843-9
pubmed: 23243265
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9
pubmed: 24423324
Pituitary. 2015 Jun;18(3):376-84
pubmed: 25008022
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
Nat Genet. 2015 Jan;47(1):31-8
pubmed: 25485838
Neurosurg Focus. 2015 Feb;38(2):E5
pubmed: 25639323
Pituitary. 2016 Apr;19(2):222-31
pubmed: 26323592
Eur J Endocrinol. 2016 Sep;175(3):R89-96
pubmed: 27207245
Eur J Endocrinol. 2018 Jan;178(1):G1-G24
pubmed: 29046323
Eur J Endocrinol. 2018 Mar;178(3):265-276
pubmed: 29330228
Pituitary. 2018 Oct;21(5):545-555
pubmed: 30062664
Endocrine. 2019 Jan;63(1):18-26
pubmed: 30145746
Clin Neurosurg. 1969;16:185-217
pubmed: 5811707
Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8
pubmed: 8232800
J Neurosurg. 1997 Jul;87(1):44-51
pubmed: 9202264